Macomber Lori 4

What Happened

• Lori Macomber, EVP, Chief Financial Officer and Treasurer of Karyopharm Therapeutics, received an award of 32,415 restricted stock units (RSUs) on January 31, 2026. The reported acquisition price is $0.00 (award), so there was no purchase cost at grant. This is a compensation grant (not an open-market buy or sell).

Key Details

• Transaction date: 2026-01-31; Form 4 filed: 2026-02-03 (timely filing).
• Transaction type: A (Award/Grant) — 32,415 RSUs granted at $0.00.
• Shares owned following the transaction: not specified in the provided filing data.
• Footnote: RSUs convert one-for-one into common stock. Vesting: 50% on January 31, 2027 and 50% on January 31, 2028 (per the 2022 Equity Incentive Plan, as amended).
• No tax withholding, sale, or 10b5-1 plan is indicated in the reported transaction.

Context

• RSU grants are a common form of executive compensation and do not require an immediate cash outlay; they only become actual shares as they vest. Such awards are compensation-related and should not be interpreted on their own as a definitive signal of the insider’s near-term view of the stock.